A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

Trial Profile

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2018

At a glance

  • Drugs INCB 54828 (Primary)
  • Indications Cholangiocarcinoma
  • Focus Therapeutic Use
  • Acronyms FIGHT-202
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 15 Feb 2018 According to an Incyte corporation media release, initial data from this trial is expected in 2018.
    • 08 Jan 2018 Planned number of patients changed from 160 to 140.
    • 13 Dec 2017 Planned number of patients changed from 100 to 160.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top